Sensus Healthcare Q2 Revenue Misses by 50%, Net Loss Widens to $8.7M
SRTS is trading near its 52-week low of $2.66 (1.2% above the low).
Summary
Sensus Healthcare's Q2 revenue fell 68.5% to $2.29 million, missing estimates by half, and net loss widened to $8.7 million due to a tax valuation allowance. Management blamed timing of financing approvals for eight units, with revenue shifted to Q3.
Key Events · Earnings and Guidance · SRTS
-
Q2 Revenue Misses by 50%
Revenue of $2.29 million fell 68.5% year-over-year and missed consensus estimates of $4.60 million by roughly half.
-
Net Loss Widens to $8.7M
Net loss of $8.7 million ($0.53 per share) compared to $1.0 million loss a year ago, driven by a $5.7 million valuation allowance against deferred tax assets.
-
Cash Position Declines
Cash, restricted cash and equivalents fell to $15.2 million from $18.3 million at March 31, 2026, with no outstanding borrowings under the revolving credit facility.
-
Revenue Timing Shift to Q3
Management attributed the shortfall to delayed financing approvals for eight units, with those sales now expected to be recognized in Q3 2026.
Analysis · SRTS · Industrial Applications And Services
Sensus Healthcare reported Q2 revenue of $2.29 million, a 68.5% decline year-over-year and roughly half of consensus estimates. The net loss widened to $8.7 million, driven by a $5.7 million valuation allowance against deferred tax assets. Management attributed the revenue shortfall to delayed financing approvals for eight units, with those sales now expected to be recognized in Q3. The company's cash position declined to $15.2 million from $18.3 million at the end of Q1, and it has no outstanding borrowings under its revolving credit facility. The stock is trading near its 52-week low, reflecting investor concern over the company's declining revenue and liquidity.
At the time of this filing, SRTS was trading at $2.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $52M. The 52-week trading range was $2.66 to $5.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.